ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
Product List
Home / ARPOD-CV DRY SYP
ARPOD-CV DRY SYP

VERTIKA 16

Product Packing: 10X10

Product Composition: Betahistine mouth dissolving 16 mg

Product Price: MRP : 0

VERTIKA 16 Mouth Dissolving Tablets

Betahistine 16 mg Mouth Dissolving Tablets

VERTIKA 16 is a prescription formulation containing Betahistine 16 mg in a mouth dissolving tablet dosage form. Betahistine is used for selected vestibular disorders associated with vertigo according to approved indications and individual clinical assessment.

Betahistine acts mainly through histamine receptor pathways and is thought to influence microcirculation and vestibular compensation. Treatment selection, dose and duration should follow the approved product label and qualified medical advice.

Composition

Each mouth dissolving tablet contains:

·         Betahistine - 16 mg

·         Excipients - q.s.

 

Dosage form: Mouth Dissolving Tablet

Pack size: 10 x 10 tablets

Uses of VERTIKA 16

VERTIKA 16 may be prescribed for selected vestibular conditions where Betahistine therapy is approved and clinically appropriate.

·         Symptomatic management of vertigo associated with selected vestibular disorders

·         Management of symptoms associated with Ménière's syndrome/disease where Betahistine is indicated

·         Support for reduction of recurrent dizziness or spinning sensation in appropriately diagnosed patients

·         Other approved vestibular uses as determined by the treating clinician

Vertigo can have many causes. Persistent, severe, sudden or neurologically associated dizziness requires appropriate medical evaluation.

How VERTIKA 16 Works

VERTIKA 16 contains Betahistine, a histamine-related medicine used in selected vestibular disorders:

Histamine receptor activity: Betahistine has agonist activity at H1 receptors and antagonist activity at H3 receptors.

Inner-ear microcirculation: Its pharmacologic actions may help influence blood flow and pressure regulation within inner-ear structures.

Vestibular compensation: Betahistine may support central vestibular compensation in appropriately diagnosed patients.

Clinical response varies according to the underlying condition, treatment duration and individual patient factors.

Dose selection and treatment duration must follow the approved product label and prescribing clinician's advice.

 

Dosage and Direction for Use

Use VERTIKA 16 exactly as prescribed. Dose and duration vary according to the diagnosis, symptom pattern, response and other clinical factors.

Place or take the mouth dissolving tablet according to the approved product instructions and the prescriber's directions.

Do not exceed the prescribed dose or alter the treatment schedule without professional advice.

Improvement may not be immediate in every patient; continue treatment only for the duration advised by the prescriber.

Possible Side Effects

Possible unwanted effects may include:

·         Headache

·         Nausea, indigestion or mild gastrointestinal discomfort

·         Abdominal bloating or other digestive symptoms in some individuals

·         Rare hypersensitivity reactions, including skin reactions, may occur

·         Seek prompt medical attention for facial or throat swelling, breathing difficulty, severe rash or other signs of a serious allergic reaction.

Persistent or troublesome adverse effects should be discussed with the treating healthcare professional.

Precautions and Contraindications

Before using VERTIKA 16, the prescriber should review the diagnosis, medical history and concomitant medicines. Important precautions include:

·         Do not use in patients with known hypersensitivity to Betahistine or formulation ingredients.

·         Betahistine is generally contraindicated in patients with pheochromocytoma according to standard prescribing information.

·         Use caution in patients with a history of peptic ulcer disease because gastrointestinal symptoms may occur.

·         Patients with bronchial asthma should be monitored appropriately during treatment.

·         Vertigo associated with acute neurological symptoms, fainting, severe headache, weakness, speech disturbance or other red flags requires urgent assessment rather than self-treatment.

·         Pregnancy, breastfeeding, children, older adults and patients with significant chronic conditions require individualized professional guidance.

·         Keep out of reach of children and store according to the approved pack instructions.

·         Drug Interaction Considerations

·         Antihistamines may theoretically reduce the effect of Betahistine, while monoamine oxidase (MAO) inhibitors may increase Betahistine exposure. Clinical relevance depends on the individual medicines and patient.

·         Patients should provide the prescriber with a complete list of prescription medicines, OTC products and supplements before starting treatment.

Business Growth Opportunity with VERTIKA 16

VERTIKA 16 offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add a Betahistine 16 mg mouth dissolving tablet to their vertigo and vestibular-care prescription portfolio.

Vertigo and vestibular symptom management represent established healthcare segments. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

 

Key Business Advantages

·         Single-ingredient vestibular-care formulation

·         Betahistine 16 mg

·         Mouth dissolving tablet dosage form

·         Convenient 10 x 10 pack configuration

·         Suitable addition to ENT, neurology and general prescription portfolios

·         Opportunity for ethical promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for VERTIKA 16

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for VERTIKA 16 in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

 

Franchise Support May Include

·         Monopoly-based territory opportunities, subject to availability

·         Promotional materials and visual aids

·         Product information and marketing support

·         Reliable supply coordination

·         Access to a growing pharmaceutical product portfolio

·         Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for VERTIKA 16 and other quality-focused healthcare products.

Third-Party Manufacturing Support for Betahistine 16 mg Mouth Dissolving Tablets

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to VERTIKA 16 under their own brand, subject to applicable licensing, prescription-drug, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

·         Customized product and pack requirements, subject to regulatory feasibility

·         Private-label manufacturing opportunities

·         Customized packaging and branding support

·         Product label and pack configuration assistance

·         Manufacturing coordination through suitable licensed facilities

·         Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand a vertigo and vestibular-care prescription portfolio.

Frequently Asked Questions About VERTIKA 16

1. What is VERTIKA 16?

VERTIKA 16 is a mouth dissolving tablet formulation containing Betahistine 16 mg.

2. What is VERTIKA 16 used for?

It may be prescribed for selected vestibular disorders associated with vertigo, including approved use in Ménière's syndrome/disease where clinically appropriate.

3. How should VERTIKA 16 be taken?

Take VERTIKA 16 exactly according to the approved product instructions and as directed by a qualified healthcare professional.

4. Can VERTIKA 16 cause stomach discomfort?

Yes. Nausea, indigestion or mild gastrointestinal discomfort can occur in some individuals.

5. Who should use Betahistine with caution?

Patients with bronchial asthma or a history of peptic ulcer disease should use Betahistine under appropriate medical supervision. It is generally contraindicated in pheochromocytoma.

6. Does VERTIKA 16 work immediately for vertigo?

Response varies. Improvement may take time depending on the underlying condition and individual response, so treatment duration should follow the prescriber's advice.

7. Is a PCD Pharma Franchise available for VERTIKA 16?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Betahistine 16 mg mouth dissolving tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

VERTIKA 16 product information in this document is for general professional and business information. Exact approved indications, dosage, contraindications, warnings, interactions, administration instructions, duration of use, excipients and regulatory status must be verified against the current approved product label and applicable prescribing information before prescribing, dispensing, use or promotion. This document is not a substitute for professional medical advice.

Contact